Form 8-K - Current report:
SEC Accession No. 0001437749-26-020562
Filing Date
2026-06-15
Accepted
2026-06-15 06:23:55
Documents
13
Period of Report
2026-06-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20260610_8k.htm   iXBRL 8-K 47482
2 EXHIBIT 10.1 ex_975585.htm EX-10.1 117276
  Complete submission text file 0001437749-26-020562.txt   331497

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA flna-20260611.xsd EX-101.SCH 3580
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE flna-20260611_def.xml EX-101.DEF 12191
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE flna-20260611_lab.xml EX-101.LAB 16409
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE flna-20260611_pre.xml EX-101.PRE 12461
16 EXTRACTED XBRL INSTANCE DOCUMENT sava20260610_8k_htm.xml XML 3089
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
FILANA THERAPEUTICS, INC. (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 261088974
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)